{ "vercy": "1.0-draft", "publication": { "status": "research-draft", "adjudicationStatus": "unreviewed", "publishableCanonical": false, "generatedAt": "2026-09-12T09:46:20Z", "providers": [ "Codex" ], "breadth": "recalled by Codex without web access - no source was read", "missingProviders": [], "pass": 2, "cost": { "grok": { "seconds": 22.0, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a09501-8630-7451-b38c-dab2e7949ec0\n--------\nuser\nDescribe what is already known about one registered thing. Answer as JSON only, no prose around it.\n\nThing: flubromazolam\nSense to describe: (none recorded)\nDomain code: PHY.MAT\nAlso known as: (none)\n\n\nContext for this batch of 1001 things:\n# Batch 043: 1001 r", "usd": 0.0, "recall": true }, "codex": { "seconds": 80.8, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a09501-862b-7440-9023-a725a59124b2\n--------\nuser\nYou are drafting a Vercy meta-model for one registered thing. Answer as JSON only, no prose around it.\n\nThing: flubromazolam\nRegistry id: vr.tr.flubromazolam\nPlane / domain: PHY / PHY.MAT\nRegistry definition: (none recorded)\nNames folded into this entry: (none" } }, "enrichment": { "pass": 3, "engine": "claude", "producedAt": "2026-10-06T12:00:00Z", "ingestedAt": "2026-10-06T08:55:53+00:00", "fields": [ "agent_conduct", "ethics", "failure_modes_and_hazards", "owners", "standards_and_regulation", "visual_identification" ] }, "gate": { "passed": true, "version": "1.0", "at": "2026-10-07T10:10:31+00:00", "evidence": [ "completeness 1.00", "sense: Wikidata description", "2 live sources", "review by codex: pass" ] } }, "metaModel": { "id": "THING-Q5462609", "registryId": "vr.tr.flubromazolam", "name": "flubromazolam", "version": "0.1.0-research.1", "entryKind": "thing", "family": "Thing Registry", "domain": [ "PHY.MAT" ], "status": "research-draft" }, "canonicalUrl": "https://ver.cy/models/thing/q5462609/", "model": { "registry_id": "vr.tr.flubromazolam", "name": "flubromazolam", "purpose": "Enable an agent to recognize flubromazolam, assess the identity and condition of material containing it, and determine evidence-supported handling and regulatory actions.", "definition": "Flubromazolam is a synthetic brominated and fluorinated triazolobenzodiazepine that acts as a positive allosteric modulator of GABA-A receptors and is known for potent sedative effects.", "scope_statement": "This model owns vr.tr.flubromazolam in PHY / PHY.MAT: the chemical substance, its distinguishing identity, material properties, analytical recognition, substance-specific hazards, and jurisdiction-dependent restrictions.", "in_scope": [ "Molecular identity and differentiation from similarly named benzodiazepines", "Purity, concentration, impurities, and chemical form of flubromazolam material", "Physical state, measured properties, and stability under recorded conditions", "Analytical confirmation in reference materials, mixtures, and biological matrices", "Substance-specific hazard evidence and dated regulatory identity" ], "out_of_scope": [ "Manufacturing and synthesis procedures", "Finished tablet, liquid product, packaging, and brand models", "Individual patient diagnosis, treatment, or dosing", "Separate models of metabolites and other benzodiazepines", "Drug-market organisations and distribution events" ], "distinguishing_features": [ "Require the methylated triazole-fused benzodiazepine structure with bromine and a 2-fluorophenyl group; name similarity alone cannot distinguish flubromazolam from flubromazepam. Structural reference: [WHO critical review](https://www.who.int/docs/default-source/controlled-substances/43rd-ecdd/final-flubromazolam-a.pdf).", "Check molecular formula C17H12BrFN4 and PubChem CID 21930924 against the resolved structure, rather than accepting either identifier alone. Reference: [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Flubromazolam).", "Require a flubromazolam-specific analytical match; a benzodiazepine class-screen result does not establish its identity.", "Treat tablet branding, seller descriptions, colour, and apparent physical form as sample observations, not chemical identification." ], "characteristics": [ { "name": "Chemical identity", "kind": "category", "unit_or_values": "Flubromazolam; CAS 612526-40-6; structure-linked identifiers", "why_it_matters": "Anchors identification to a defined substance. CAS reference: [WHO critical review](https://www.who.int/docs/default-source/controlled-substances/43rd-ecdd/final-flubromazolam-a.pdf)." }, { "name": "Material form", "kind": "category", "unit_or_values": "Characterized parent compound, documented alternative chemical form, solution constituent, mixture constituent, or unresolved", "why_it_matters": "Prevents applying parent-compound properties to an uncharacterized preparation." }, { "name": "Assay and impurity profile", "kind": "measurement", "unit_or_values": "Mass fraction % with assay basis, uncertainty, method, and identified impurities", "why_it_matters": "Distinguishes chemical purity from chromatographic area percentage and seller claims." }, { "name": "Matrix-specific concentration", "kind": "measurement", "unit_or_values": "mg/g, mg/mL, or ng/mL with matrix, sampling method, and uncertainty", "why_it_matters": "Separates the amount of flubromazolam from the amount of material containing it." }, { "name": "Physical condition", "kind": "state", "unit_or_values": "Observed phase, temperature in °C, pressure in kPa, precipitation, and evidence of degradation", "why_it_matters": "Makes physical observations interpretable and supports decisions about sample suitability." }, { "name": "Thermal and solubility properties", "kind": "measurement", "unit_or_values": "Melting or decomposition temperature in °C; boiling temperature with pressure; solubility in mg/mL with solvent, pH, and temperature; measured, predicted, or unknown", "why_it_matters": "Prevents estimates or preparation-specific measurements from becoming universal constants." }, { "name": "Analytical identification status", "kind": "state", "unit_or_values": "Suspected, screened, confirmed, inconclusive, or not detected within stated method limits", "why_it_matters": "Keeps detection confidence separate from labels and class-level screening." }, { "name": "Hazard evidence", "kind": "relation", "unit_or_values": "Endpoint linked to study or case evidence, exposure context, co-exposures, and uncertainty", "why_it_matters": "Supports hazard assessment without treating every reported outcome as attributable to flubromazolam alone." }, { "name": "Regulatory and occupational classification", "kind": "category", "unit_or_values": "Jurisdiction, effective date, controlled-substance category, applicable GHS classification, exposure limit if established, and authoritative source", "why_it_matters": "Separates drug control, workplace hazard classification, and authorization for a particular activity." } ], "affordances": [ "Resolve a claimed flubromazolam identity against structure-linked references.", "Request or evaluate confirmatory analysis appropriate to the sample matrix.", "Assess whether purity, concentration, and storage evidence support use as an analytical material.", "Flag uncertain or discrepant material for segregation and specialist review.", "Check documented authorization before possession, transfer, analysis, or disposal.", "Link exposure evidence to a clinical or toxicological assessment without generating a dosing recommendation." ], "agent_conduct": { "may": [ "Describe flubromazolam as an unlicensed designer benzodiazepine and its legal status.", "Share harm-reduction information about its potency and long action." ], "must_not": [ "Provide any guidance on making, obtaining or dosing it.", "Help anyone buy, sell, ship or conceal it.", "Assist in giving it to anyone without their knowledge.", "Present it as a safe alternative to prescribed medicines." ], "requires_human": [ "Handling suspected samples, which belongs to licensed forensic laboratories and authorities." ] }, "ethics": { "considerations": [ "Designer benzodiazepines have been used in drug-facilitated assault, so covert dosing is a serious harm.", "People who use drugs deserve information without stigma." ], "affected_parties": [ "People who use drugs", "Potential victims of covert dosing", "Emergency responders" ] }, "owners": { "steward": "Nobody holds it lawfully outside licensed research where controlled; drug control authorities regulate it.", "master_systems": [ "National controlled substance schedules" ] }, "visual_identification": [ "It cannot be identified by sight; suspected tablets or powders need forensic laboratory testing." ], "failure_modes_and_hazards": [ "Very potent and long-acting, causing deep sedation and amnesia.", "Breathing failure when combined with opioids or alcohol." ], "standards_and_regulation": [ "Convention on Psychotropic Substances 1971, Schedule IV, United Nations." ], "what_it_is_for": [ "Flubromazolam is encountered in research on psychoactive substances, forensic analysis and toxicological investigations.", "It also occurs in unregulated drug supplies, where its presence may be relevant to investigating unexpected sedation or identifying unknown material." ] }, "sources": [ { "id": "wikidata", "title": "Wikidata item Q5462609: flubromazolam", "url": "https://www.wikidata.org/wiki/Q5462609", "url_status": "live", "what_it_supports": "identity and sense of the item", "checked_by": "wikidata-api" }, { "id": "wikipedia-en", "title": "Wikipedia: Flubromazolam", "url": "https://en.wikipedia.org/wiki/Flubromazolam", "url_status": "live", "what_it_supports": "general description of the item", "checked_by": "wikidata-api sitelink" } ], "structure": { "bundles": [ { "id": "flubromazolam-identity", "name": "Flubromazolam identity", "description": "Resolve the registered substance and prevent confusion with neighbouring benzodiazepines.", "rationale": "Closely related names and structures make mistaken substitution consequential.", "layers": [ { "id": "structure-and-identifiers", "name": "Structure and identifiers", "description": "Connect the registry entry to a chemically explicit identity.", "findings": [ { "id": "structure-anchored-identity", "name": "Structure-anchored identity", "description": "Record the resolved structure and reconcile identifiers before accepting a flubromazolam label.", "questions": [ { "text": "Which authoritative structure record defines flubromazolam for this entry?", "kind": "definition", "id": "structure-anchored-identity-q01" }, { "text": "Do the CAS number, PubChem CID, and supplied structural identifier resolve to the same chemical entity?", "kind": "provenance", "id": "structure-anchored-identity-q02" } ] } ] }, { "id": "near-neighbour-boundaries", "name": "Near-neighbour boundaries", "description": "Separate molecular identity from similar names and product claims.", "findings": [ { "id": "benzodiazepine-confusion-check", "name": "Benzodiazepine confusion check", "description": "Require an explicit structural comparison when records mention flubromazepam, bromazolam, or alprazolam.", "questions": [ { "text": "Which structural features distinguish the candidate from each plausible neighbouring benzodiazepine?", "kind": "boundary", "id": "benzodiazepine-confusion-check-q01" }, { "text": "Does the name describe an analytically identified substance or merely a claimed tablet or liquid ingredient?", "kind": "provenance", "id": "benzodiazepine-confusion-check-q02" } ] } ] } ] }, { "id": "flubromazolam-material-condition", "name": "Flubromazolam material condition", "description": "Describe the actual material to which identity and property claims apply.", "rationale": "A reference powder, solution, and mixed tablet require different interpretations of assay and condition.", "layers": [ { "id": "composition-and-assay", "name": "Composition and assay", "description": "Establish chemical form, purity, concentration, and sample representativeness.", "findings": [ { "id": "quantified-parent-content", "name": "Quantified parent content", "description": "Keep parent-substance content separate from total sample mass, solvent, excipients, and other active substances.", "questions": [ { "text": "What flubromazolam content was measured, on which chemical-form and mass or volume basis?", "kind": "measurement", "id": "quantified-parent-content-q01" }, { "text": "Which impurities or co-constituents were tested for, and how representative was the sampled portion?", "kind": "measurement", "id": "quantified-parent-content-q02" } ] } ] }, { "id": "phase-and-stability", "name": "Phase and stability", "description": "Track condition-dependent physical properties and changes during storage.", "findings": [ { "id": "condition-qualified-properties", "name": "Condition-qualified properties", "description": "Accept thermal, solubility, and stability values only with their experimental or predictive basis.", "questions": [ { "text": "Which flubromazolam thermal and solubility values are experimental, and what form, solvent, temperature, and pressure do they describe?", "kind": "measurement", "id": "condition-qualified-properties-q01" }, { "text": "What evidence of precipitation, concentration change, or degradation requires reanalysis or withdrawal of this material?", "kind": "action", "id": "condition-qualified-properties-q02" } ] } ] } ] }, { "id": "flubromazolam-analytical-recognition", "name": "Flubromazolam analytical recognition", "description": "Distinguish screening from defensible identification and quantification.", "rationale": "WHO reports that some benzodiazepine immunoassays missed subsequently confirmed flubromazolam. Reference: [WHO critical review](https://www.who.int/docs/default-source/controlled-substances/43rd-ecdd/final-flubromazolam-a.pdf).", "layers": [ { "id": "confirmatory-specificity", "name": "Confirmatory specificity", "description": "Assess whether a method specifically supports flubromazolam identification.", "findings": [ { "id": "reference-supported-confirmation", "name": "Reference-supported confirmation", "description": "Require documented reference comparison, interference assessment, and acceptance criteria.", "questions": [ { "text": "Which validated chromatographic and spectrometric criteria confirm flubromazolam in this matrix?", "kind": "measurement", "id": "reference-supported-confirmation-q01" }, { "text": "Which authenticated reference material or traceable reference data support that identification?", "kind": "provenance", "id": "reference-supported-confirmation-q02" } ] } ] }, { "id": "matrix-and-metabolite-interpretation", "name": "Matrix and metabolite interpretation", "description": "Keep parent detection, metabolite evidence, and test sensitivity distinct.", "findings": [ { "id": "bounded-detection-meaning", "name": "Bounded detection meaning", "description": "Interpret each result using its matrix, target analyte, preparation, and detection limits.", "questions": [ { "text": "Was the measured analyte parent flubromazolam or a separately identified metabolite?", "kind": "boundary", "id": "bounded-detection-meaning-q01" }, { "text": "What detection limits, matrix effects, and sample timing constrain a negative or quantitative result?", "kind": "measurement", "id": "bounded-detection-meaning-q02" } ] } ] } ] }, { "id": "flubromazolam-hazard-evidence", "name": "Flubromazolam hazard evidence", "description": "Connect substance-specific effects to their evidence and limits.", "rationale": "WHO describes high potency, prolonged central nervous system depression, and serious intoxications. Reference: [WHO critical review](https://www.who.int/docs/default-source/controlled-substances/43rd-ecdd/final-flubromazolam-a.pdf).", "layers": [ { "id": "effects-and-persistence", "name": "Effects and persistence", "description": "Separate observed effects from mechanistic and kinetic interpretations.", "findings": [ { "id": "qualified-effect-profile", "name": "Qualified effect profile", "description": "Record effect duration and pharmacological evidence without converting limited observations into universal thresholds.", "questions": [ { "text": "Which flubromazolam-specific studies support the recorded receptor effects and adverse-effect endpoints?", "kind": "provenance", "id": "qualified-effect-profile-q01" }, { "text": "How were persistence and elimination estimated, and what sample size and exposure context limit those estimates?", "kind": "measurement", "id": "qualified-effect-profile-q02" } ] } ] }, { "id": "co-exposure-and-handling", "name": "Co-exposure and handling", "description": "Support exposure prevention while preserving uncertainty about causation.", "findings": [ { "id": "contextual-hazard-decisions", "name": "Contextual hazard decisions", "description": "Keep co-exposures, dependence evidence, and material-handling controls explicit.", "questions": [ { "text": "Which reported harms involved flubromazolam alone, and which involved other depressants or uncertain composition?", "kind": "provenance", "id": "contextual-hazard-decisions-q01" }, { "text": "Which documented containment and exposure-response procedures apply to this material form and activity?", "kind": "action", "id": "contextual-hazard-decisions-q02" } ] } ] } ] }, { "id": "flubromazolam-controlled-handling", "name": "Flubromazolam controlled handling", "description": "Connect chemical identity to dated restrictions and accountable material custody.", "rationale": "EUDA reports international control in 2021; operational decisions still require current jurisdiction-specific authority. Reference: [EUDA benzodiazepine market report](https://www.euda.europa.eu/publications/eu-drug-markets/new-psychoactive-substances/distribution-and-supply/benzodiazepines_en).", "layers": [ { "id": "jurisdiction-and-activity", "name": "Jurisdiction and activity", "description": "Determine restrictions for the proposed activity at the relevant place and time.", "findings": [ { "id": "dated-authorization", "name": "Dated authorization", "description": "Do not treat a research-chemical description or a historical schedule as present authorization.", "questions": [ { "text": "Which current legal instrument covers flubromazolam and this material form in the relevant jurisdiction?", "kind": "provenance", "id": "dated-authorization-q01" }, { "text": "What documented authorization is required for the proposed possession, analysis, transfer, or disposal?", "kind": "action", "id": "dated-authorization-q02" } ] } ] }, { "id": "custody-and-disposition", "name": "Custody and disposition", "description": "Maintain a traceable relationship between the identified substance and controlled physical holdings.", "findings": [ { "id": "reconciled-material-history", "name": "Reconciled material history", "description": "Link flubromazolam assay results to the correct lot, container, inventory record, and disposition.", "questions": [ { "text": "Which custody and container records connect the tested sample to the material currently held?", "kind": "provenance", "id": "reconciled-material-history-q01" }, { "text": "What authorized disposition follows from an identity discrepancy, failed assay, or expired material qualification?", "kind": "action", "id": "reconciled-material-history-q02" } ] } ] } ] }, { "id": "evidence-and-external-alignment", "name": "Evidence and external alignment", "description": "What the world already says about this thing, gathered so the model can be checked against it.", "rationale": "A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.", "layers": [ { "id": "reported-evidence", "name": "Reported evidence", "description": "Findings from the breadth pass, kept separate from the structural claims.", "findings": [ { "id": "evidence-confidence-notes", "name": "Check these first", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "This is a recall-based description; no sources were consulted.", "Verify the registry identity, analytical reference material purity and any physical constants before laboratory use.", "Human pharmacokinetic data and potency estimates require source checking; no established therapeutic dose or current jurisdiction-specific legal status is asserted." ], "questions": [ { "id": "evidence-confidence-notes-q01", "text": "Which of these check these first hold for the sense of flubromazolam this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-identifiers", "name": "Identifiers and schemes", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "scheme": "CAS Registry Number", "value_or_pattern": "612526-40-6", "note": "Identifier for flubromazolam." }, { "scheme": "Molecular formula", "value_or_pattern": "C17H12BrFN4", "note": "Describes elemental composition but does not uniquely identify molecular structure." } ], "questions": [ { "id": "evidence-identifiers-q01", "text": "Which of these identifiers and schemes hold for the sense of flubromazolam this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-real-world-use", "name": "Real-world use", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Encountered in the unregulated market as a designer benzodiazepine.", "Used as an analytical reference substance in forensic toxicology.", "Studied in research on benzodiazepine pharmacology and intoxication." ], "questions": [ { "id": "evidence-real-world-use-q01", "text": "Which of these real-world use hold for the sense of flubromazolam this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-measurements", "name": "Typical measurements", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "quantity": "Molar mass", "typical_range": "371.21", "unit": "g/mol" } ], "questions": [ { "id": "evidence-measurements-q01", "text": "Which of these typical measurements hold for the sense of flubromazolam this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-failure-modes-and-hazards", "name": "Failure modes and hazards", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Profound sedation, impaired coordination and amnesia.", "Severe intoxication can involve prolonged unconsciousness and respiratory depression.", "Combining it with opioids, alcohol or other central nervous system depressants increases overdose risk.", "Repeated use can produce dependence; abrupt withdrawal can cause seizures.", "Unregulated products can have incorrect identities, variable concentrations or uneven distribution, making exposure unpredictable." ], "questions": [ { "id": "evidence-failure-modes-and-hazards-q01", "text": "Which of these failure modes and hazards hold for the sense of flubromazolam this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-regional-variation", "name": "Regional variation", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Legal controls and the treatment of analogues differ by jurisdiction and require current verification." ], "questions": [ { "id": "evidence-regional-variation-q01", "text": "Which of these regional variation hold for the sense of flubromazolam this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-neighbours", "name": "Neighbouring kinds and how to tell them apart", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "name": "Bromazolam", "difference": "Bromazolam lacks the fluorine substituent on the pendant phenyl ring present in flubromazolam." }, { "name": "Flualprazolam", "difference": "Flualprazolam has chlorine where flubromazolam has bromine on the fused benzene ring." }, { "name": "Flubromazepam", "difference": "Flubromazepam is a benzodiazepinone rather than a compound with flubromazolam's fused triazole ring." } ], "questions": [ { "id": "evidence-neighbours-q01", "text": "Which of these neighbouring kinds and how to tell them apart hold for the sense of flubromazolam this model covers, and on what evidence?", "kind": "provenance" } ] } ] } ] } ] }, "openQuestions": [ "Is an EC number authoritatively assigned to this exact substance, and which additional identifiers reliably resolve to the same structure?", "Which melting, decomposition, boiling, solubility, and storage-stability values have experimental support for characterized flubromazolam material?", "Which current GHS classifications and occupational exposure limits, if any, apply to the exact material and jurisdiction?", "How robust are flubromazolam-specific human pharmacokinetic, interaction, and dependence findings beyond small studies and case reports?", "Which current legal instruments and activity-specific authorizations apply in the intended jurisdiction, including treatment of mixtures and reference solutions?" ], "statistics": { "bundles": 6, "layers": 11, "findings": 17, "questions": 27 } }